Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.20.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating Costs and Expenses:    
General and administrative $ 1,393,000 $ 1,154,000
Research and development 1,635,000 2,418,000
Total Operating Costs and Expenses 3,028,000 3,572,000
Loss from Operations (3,028,000) (3,572,000)
Other Income :    
Interest income 38,000 44,000
Total Other Income 38,000 44,000
Net Loss (2,990,000) (3,528,000)
Net Loss Attributable to Non-controlling Interest (26,000) (16,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,964,000) (3,512,000)
Net Loss Attributable to Common Stockholders $ (3,430,000) $ (3,971,000)
Net Loss Per Share - Basic and Dilutive $ (0.20) $ (0.25)
Weighted average number of shares outstanding during the period - Basic and Dilutive 17,093,920 15,656,784
Series A Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact $ (62,000) $ (61,000)
Series B Preferred Stock [Member]    
Other Income :    
Net Loss Attributable to Non-controlling Interest 0  
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0  
Preferred Stock Dividends, Income Statement Impact $ (404,000) $ (398,000)